Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NBIX

3 Specialty Pharma Stocks Addressing Unmet Medical Needs

The specialty pharma sector is leading the charge in developing life-changing solutions for rare and chronic conditions. Amid this backdrop, investors might consider adding three fundamentally solid specialty pharma stocks, namely, Ipsen S.A. (IPSEY), ACADIA Pharmaceuticals (ACAD), and Neurocrine Biosciences (NBIX) in their portfolios. Read on….

StockNews.com

3 Top Growth Stocks to Buy at a Discount This Month

According to analysts, here are three top-notch mid-cap growth stocks to snag at a discount now.

Barchart

3 Pharma Stocks to Buy for Potential Financial Fortunes

Amid surging medicine demand and ongoing drug shortages, the pharmaceutical industry thrives, driving improved patient outcomes and promising growth opportunities for investors. So, it could be wise to invest in quality pharma stocks ACADIA Pharmaceuticals (ACAD), Neurocrine Biosciences (NBIX), and Supernus Pharmaceuticals (SUPN), which can help you fetch potential financial…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.

Investors Business Daily

AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base

Artificial intelligence plays HubSpot and Arista Networks are among five stocks near buy points with big market news on tap.

Investors Business Daily

3 Pharma Stock Buys With Accelerating Gains

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

StockNews.com

Will These 3 Pharma Stocks Leave Investors Triumphant in 2024?

The pharmaceutical industry is undergoing a transformative shift driven by the advent of personalized drugs, technological innovations, and growing usage. Against this backdrop, does the inclusion of pharma stocks CytomX Therapeutics (CTMX), Merck & Co (MRK), and Neurocrine Biosciences (NBIX) in your portfolio appear wise? Let’s find out….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

StockNews.com

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

StockNews.com

Pharma Showdown: Evaluating Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX) Stock Performance Under the Microscope

The pharmaceutical landscape is evolving in response to the shift toward sedentary living and is driven by substantial investments in R&D and advanced technologies. Against this backdrop, which of the two pharma stocks, Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX), could generate better returns? Let’s find out….

StockNews.com

3 A-Rated Pharma Buys for October

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), Novo Nordisk (NVO), and AstraZeneca PLC (AZN), which are rated an A (Strong Buy) in our…

StockNews.com

Dow Jones Futures Rise After Market Correction Worsens; Meta Near Buy Point With AI News Due

The market correction hit new lows Tuesday. Investors need to be patient. Meta is set to unveil VR hardware and AI tools at its Meta Connect event.

Investors Business Daily

The $660 Million Opportunity That's Driving IBD Stock Of The Day Neurocrine Biosciences Higher

Neurocrine is Tuesday's IBD Stock Of The Day. After it unveiled promising results for a genetic disease drug, NBIX stock is on the rise.

Investors Business Daily

3 A-Rated Pharma Stocks to Buy Today

The pharmaceutical industry is expected to grow in the upcoming years, propelled by continual advancements in medicine, aiming to meet the escalating demands for chronic disease treatment and address the needs of an aging population. Therefore, quality pharma stocks Neurocrine Biosciences (NBIX), AbbVie Inc. (ABBV), and Novo Nordisk A/S (NVO),…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?

Neurocrine said Tuesday its experimental drug could help lower steroid use for patients with a rare, adrenal disease. NBIX stock surged.

StockNews.com

3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

StockNews.com

Healthy Returns: This A Rated Healthcare Stock Is a Must-Watch for May

Given the pharmaceutical industry’s robust growth prospects, drug-maker Neurocrine Biosciences’ (NBIX) stock is worth watching ahead of its first-quarter earnings next week. Read on….

Investors Business Daily

Neurocrine Reports 3,000% Profit Growth, But Shares Unexpectedly Tumble

Neurocrine reported soaring fourth-quarter profit Monday and issued in-line guidance for Ingrezza. But NBIX stock toppled.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Hyper-Growth Stocks to Buy for Big Gains

With recent economic data showing promise, the chances of a soft landing for the economy are increasing. Hence, it could be wise to invest in fundamentally sound stocks CVS Health (CVS), Ooma (OOMA), and Neurocrine Biosciences (NBIX), which possess solid growth attributes. Read on….

Investors Business Daily

Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally

Dow giant UnitedHealth is among 5 stocks holding key support while the overall market weakens.

Investors Business Daily

Oil Firm Eyeing 3,755% Q4 Growth Leads 24 Fastest-Growing Stocks

With analysts expecting a whopping 3,755% Q4 growth, HF Sinclair leads this list of 24 of today's fastest-growing stocks.

Investors Business Daily

Dow Jones Futures Rise: 5 Stocks Near Buy Points In Market Rally; Tesla FSD Beta Expands Widely

The S&P 500 still faces its 200-day line with key economic data looming. Tesla FSD Beta gets a wide release after TSLA stock jumped from bear market lows.

Investors Business Daily

ANET Stock, NBIX, WMB, MPLX, 7 Other Tickers Appear On IBD Watchlists

IBD stock screens are regularly updated to add new stocks to watch, as well as weed out those that have started to show weakness. In the tables below, you'll see which stocks have been added to or removed from lists like the IBD 50, Sector Leaders and the IBD Big…

Investors Business Daily

Blazing Hot Neurocrine Biosciences, With 40% Run This Year, Extends Breakout On Quarterly Beat

Neurocrine Biosciences beat third-quarter forecasts and raised its Ingrezza outlook for 2022, leading NBIX stock to jump Tuesday.

Investors Business Daily

Dow Jones Futures Await Jobs Report; AMD Warns, Elon Musk Wins Twitter Trial Delay

The major indexes reversed from short-term levels Thursday with the September jobs report on tap. Twitter fell as Elon Musk made new demands. AMD warned late.

1 2

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Brian Abrahams

64 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations